Uekado Y
Department of Urology, Wakayama Medical College.
Hinyokika Kiyo. 1991 Aug;37(8):825-31.
From November 1984 to April 1989, 40 patients with advanced prostate cancer were treated with chemohormonal therapy consisting of orchiectomy, diethylstilbestrol diphosphate, CDDP and cyclophosphamide. Of the 40 patients, 23 had partial response, 15 had stable disease and 2 had progression of disease at 3 months after the initiation of the treatment. In analysis of survival rate, the 5-year survival rate of all cases was 61.5%. The prognosis of the patients with low grade tumors was better than those with high grade tumors. In stages C and D patients, the survival rate was 75%, and 56%, respectively. Relapse occurred in 5 patients. The interval between start of treatment and relapse was approximately 20 months. Relapse rate was lower than that of 23 patients treated with hormonal treatment alone during the same periods (p less than 0.05). Gastrointestinal symptoms including different degrees of nausea and vomiting were observed in about half of the patients. Myelosuppression was seen in a few cases. These findings suggest the effectiveness of chemohormonal therapy for newly diagnosed advanced prostate cancer.